Alexion Pharmaceutic
ALXN
Delayed Nasdaq - 08/17 10:00:00 pm
116USD
-1.09%
Prev.117.2800
Open117.0700
High117.2800
Low115.4500
Volume1 109 413
Financials
Sales 2018 4 043 M
EBIT 2018 2 012 M
R. net 2018 237 M
Debt 2018 1 083 M
Rend. 2018 -
P/E ratio 2018 56,42
P/E ratio 2019 18,45
EV / Sales 2018 6,66x
EV / Sales 2019 5,00x
Capitalization 25 852 M
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded...
Sector :
Biopharmaceuticals
Calendar :
2018-10-25 Earnings Release
Trading Rating :
Investor Rating :
Latest news
07/27CORRECTION : Earns-Alexion Pharmaceuticals story
AQ
07/26ALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
AQ
07/26ALEXION PHARMACEUTICALS : Researchers at Alexion Pharmaceuticals, Inc. Target Alpha 1-Antitrypsin Deficiency (SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency)
AQ
07/26ALEXION PHARMACEUTICALS : Beats Forecasts With 33% Rise in Adjusted EPS
DJ
07/26ALEXION : 2Q Earnings Snapshot
AQ
07/26ALEXION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
07/26ALEXION PHARMACEUTICALS : Reports Second Quarter 2018 Results
BU
07/24ALEXION PHARMACEUTICALS : Free Technical Research Reports on Biotech Stocks -- Alkermes, Alnylam Pharma, Altimmune, and Alexion Pharma
PR
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralNeutral
Resistance128137147
Spread/Res.-9,1%-15%-21%
Spread/Supp.0,59%9,4%7,6%
Support115106108